Connection

JOHN VIERLING to Ursodeoxycholic Acid

This is a "connection" page, showing publications JOHN VIERLING has written about Ursodeoxycholic Acid.
Connection Strength

0.829
  1. Primary biliary cholangitis. Lancet. 2024 09 14; 404(10457):1053-1066.
    View in: PubMed
    Score: 0.220
  2. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021 06; 74(6):1344-1354.
    View in: PubMed
    Score: 0.171
  3. Future Treatment Options in PBC. Semin Liver Dis. 2005 Aug; 25(3):347-63.
    View in: PubMed
    Score: 0.059
  4. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N Engl J Med. 2024 02 29; 390(9):783-794.
    View in: PubMed
    Score: 0.053
  5. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. N Engl J Med. 2024 02 29; 390(9):795-805.
    View in: PubMed
    Score: 0.052
  6. Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. Aliment Pharmacol Ther. 2024 01; 59(2):186-200.
    View in: PubMed
    Score: 0.052
  7. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. Hepatology. 2023 08 01; 78(2):397-415.
    View in: PubMed
    Score: 0.050
  8. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. J Hepatol. 2022 08; 77(2):353-364.
    View in: PubMed
    Score: 0.046
  9. The challenges of primary biliary cholangitis: What is new and what needs to be done. J Autoimmun. 2019 12; 105:102328.
    View in: PubMed
    Score: 0.039
  10. Seladelpar (MBX-8025), a selective PPAR-d agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol. 2017 10; 2(10):716-726.
    View in: PubMed
    Score: 0.034
  11. Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016. Hepatol Int. 2016 Nov; 10(6):909-915.
    View in: PubMed
    Score: 0.032
  12. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology. 2012 Feb; 55(2):512-21.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.